Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study

NCT06068075 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT06068075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: The LEOPARD Study
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 8, 2018
Completion date
January 1, 2027
Enrollment
340 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, ewing sarcoma of bone, ewing sarcoma of soft tissue, high-grade osteosarcoma, peripheral primitive neuroectodermal tumor, peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissue